BioCardia Reports Business Highlights and Financial Results for the Second Quarter of 2024

SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapies for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The company will also host a conference call today at 4:30 p.m. ET to discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.

Recent Business Highlights